Gleneagle Gold (ASX:GLN) has positioned itself at the forefront of the medical cannabis sector, after recently entering into an agreement in relation to acquiring 100% of the issued capital of Zelda Therapeutics Pty Ltd.
Zelda has now appointed oncologist and physician scientist, Dr Noah Federman, to its Scientific Advisory Board.
Dr Federman holds extensive clinical oncology experience specialising in treating children with aggressive cancers.
His knowledge and experience in the oncology field will be highly valuable for developing rigorous medical cannabis clinical trials in cancer.
The appointment signals the strong level of medical and scientific support for Zelda's strategy to validate the efficacy of medical cannabis in key indications.
Harry Karelis, chairman for Zelda, commented:
"Zelda is now clearly positioned as a key thought-leader globally in the medical cannabis space and with numerous governments legislating to allow medical cannabis, most recently in Australia, we are uniquely placed through our relationships to accelerate the scientific understanding and clinical benefits of medical cannabis."
Dr Federman added:
"I have been aware of Mara Gordon (Zelda co-founder) and her activities for some time and have witnessed first-hand the improvement in the quality of life for my patients from her deep knowledge of the biological effects of medical cannabis.
"Focusing on robust clinical trials to show statistically significant outcomes is crucial to validating the potential of medical cannabis to provide patients in need with new treatment options."
Zelda's Scientific Advisory Board also includes:
- Dr Joe Goldstrich: An experienced specialist and physician with extensive knowledge in the use of medical cannabis to treat a variety of conditions.
- Professor Manuel Guzman: Full Professor of Biochemistry and Molecular Biology at Madrid's Complutense University and expert on the molecular mechanisms of action and role of cannabinoids in controlling cell generation and death.
- Dr Cristina Sanchez: Assistant Professor at Complutense University, Madrid Spain and specialist in the area of lipid signalling, including cannabinoids in an oncology setting Dr Donald Abrams - a cancer and integrative medicine specialist at the UCSF Osher Center for Integrative Medicine at Mount Zion and Chief of Haematology and Oncology at San Francisco General Hospital.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.